ISR - IsoRay, Inc.
| Previous Close | 0.530 |
| Open | 0.505 |
| Bid | 0.000 x 800 |
| Ask | 0.000 x 800 |
| Day's Range | 0.482 - 0.530 |
| 52 Week Range | 0.360 - 0.650 |
| Volume | 484,063 |
| Avg. Volume | 219,509 |
| Market Cap | 28.432M |
| Beta | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.113 |
| Earnings Date | Feb 9, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- ACCESSWIRE•5 days ago
IsoRay, Inc. Discusses Competitive Landscape, FDA Clearance for New Product Line and Growth Drivers in New SNNLive Video Interview with StockNewsNow.com
LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Tom LaVoy, Chairman of the Board & CEO of IsoRay, Inc. ...
- Simply Wall St.•6 days ago
Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately
For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at IsoRay Inc’sRead More...
- GlobeNewswire•6 days ago
IsoRay Announces Participation at the American Urological Association’s 2018 Annual Meeting, May 18-21, 2018
RICHLAND, Wash., May 16, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the Company’s participation at the upcoming American Urological Association (AUA) Annual Meeting, taking place on May 18-21, 2018 in San Francisco, CA. “The AUA is one of our biggest opportunities each year to share the latest information about brachytherapy with the urological community,” said Thomas LaVoy, Chairman and Chief Executive Officer of IsoRay, Inc. “We believe that Cesium-131, with its unique fast energy delivery and quick patient recovery, provides urologists with a better option for their prostate cancer patients. Dr. Benoit is a long-time researcher and advocate of Cesium-131 and we’re pleased that his participation on the prostate cancer panel will ensure that this important information is correctly presented to the urological community.
- GlobeNewswire•11 days ago
IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment
IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the upcoming release of its Build-Blu™ delivery system for real-time prostate brachytherapy. The Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room, thereby allowing clinicians to individualize the procedure to the patient’s anatomy in real time. This new product will provide an alternative solution to the approximately 25% of treatment facilities for the prostate market that are using intra-operative techniques.
- Associated Press•19 days ago
IsoRay: Fiscal 3Q Earnings Snapshot
The Richland, Washington-based company said it had a loss of 2 cents per share. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of trading on ...
- GlobeNewswire•19 days ago
IsoRay Announces Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Third Quarter-Over-Third Quarter Increase
RICHLAND, Wash., May 03, 2018-- IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and ...
- GlobeNewswire•20 days ago
IsoRay to Present at the 3rd Annual Disruptive Growth & Healthcare Conference hosted by RHK Capital
NEW YORK, NY, May 02, 2018-- IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck ...
- GlobeNewswire•26 days ago
IsoRay Announces Third Quarter Fiscal 2018 Earnings Conference Call
IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will host a teleconference to discuss third quarter fiscal 2018 financial results on Thursday, May 3, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter of fiscal 2018 ended March 31, 2018, immediately after the close of the market on May 3, 2018. The earnings release and a replay of the call will be available through the Investor Relations section of the Company’s website: https://isoray.com/about/investors/presentations/.
- ACCESSWIRE•28 days ago
Isoray (ISR) Stock: Circles Back Toward Leadership Position in Treating Prostate Cancer
Original Source: CNA Finance CORAL SPRINGS, FL / ACCESSWIRE / April 24, 2018 / If an investor pitched me on all of the positive features of IsoRay, Inc. (NYSE American: ISR ) and told me at the end of ...
- ACCESSWIRE•last month
IsoRay to Present at the Planet MicroCap Showcase 2018 on April 25 in Las Vegas, NV
RICHLAND, WA / ACCESSWIRE / April 19, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...
- GlobeNewswire•last month
IsoRay Announces Preliminary Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Year-over-Year Increase
RICHLAND, Wash, April 18, 2018-- IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and ...
- Associated Press•3 months ago
IsoRay reports 2Q loss
The Richland, Washington-based company said it had a loss of 3 cents per share. The isotope-based medical products maker posted revenue of $1.5 million in the period. The company's shares closed at 48 ...
- ACCESSWIRE•3 months ago
IsoRay, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / IsoRay, Inc. (NYSE AMERICAN: ISR ) will be discussing their earnings results in their Q2 Earnings Call to be held on February 8, 2018 at 4:30 PM Eastern Time. ...
- Simply Wall St.•3 months ago
Was IsoRay Inc’s (NYSEMKT:ISR) Earnings Decline A Part Of Broader Industry Downturn?
When IsoRay Inc (AMEX:ISR) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peersRead More...
Capital Cube•6 months agoIsoRay, Inc. :ISR-US: Earnings Analysis: Q1, 2018 By the Numbers : December 1, 2017
Categories: Yahoo FinanceGet free summary analysis IsoRay, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of IsoRay, Inc. – Accuray Incorporated, General Electric Company, Hologic, Inc., STRATA Skin Sciences, Inc., C. R. Bard, Inc. and Varian Medical Systems, Inc. (ARAY-US, GE-US, HOLX-US, SSKN-US, BCR-US and ... Read more (Read more...)
- ACCESSWIRE•6 months ago
IsoRay to Present at the 10th Annual LD Micro Main Event
Presentation on Wednesday, December 6, 2017, at 7:30 am PST / 10:30 am EST RICHLAND, WA / ACCESSWIRE / November 28, 2017 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator ...
- Associated Press•6 months ago
IsoRay reports 1Q loss
The Richland, Washington-based company said it had a loss of 3 cents per share. The isotope-based medical products maker posted revenue of $1.2 million in the period. The company's shares closed at 43 ...
